Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Melanoma

Free Subscription Articles published in Ann Surg Oncol Retrieve available abstracts of 201 articles: HTML format

Single Articles

May 2024
1. ZAGER JS, Orloff M, Ferrucci PF, Choi J, et al
   Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
   Ann Surg Oncol. 2024 May 4. doi: 10.1245/s10434-024-15293.
   PubMed     Abstract available
   
   
   April 2024
2. LIANG C, Li D, Liang Y, Xie Y, et al
   Prognostic and Predictive Significance of Ki67 in Primary Non-metastatic or Recurrent Acral Melanoma: Evidence from a Multicenter Retrospective Study.
   Ann Surg Oncol. 2024 Apr 30. doi: 10.1245/s10434-024-15327.
   PubMed     Abstract available
   
   
   
3. GREENE AC, Ziegler O, Pameijer CR, Shen C, et al
   ASO Author Reflections: Exploring the Impact-Medicaid Expansion and Improved Survival in Patients with Cutaneous Melanoma.
   Ann Surg Oncol. 2024 Apr 22. doi: 10.1245/s10434-024-15286.
   PubMed    
   
   
   
4. LEE TS, Li I, Peric B, Saw RPM, et al
   ASO Visual Abstract: Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective Randomized Trial.
   Ann Surg Oncol. 2024 Apr 18. doi: 10.1245/s10434-024-15262.
   PubMed    
   
   
   March 2024
5. GREENE AC, Ziegler O, Quattrone M, Stack MJ, et al
   Association between Medicaid Expansion and Cutaneous Melanoma Diagnosis and Outcomes: Does Where You Live Make a Difference?
   Ann Surg Oncol. 2024 Mar 29. doi: 10.1245/s10434-024-15214.
   PubMed     Abstract available
   
   
   
6. LEE TS, Spillane AJ
   ASO Author Reflections: Lymphoedema Related to Inguinal and Ilioinguinal Lymphadenectomy for Melanoma.
   Ann Surg Oncol. 2024 Mar 27. doi: 10.1245/s10434-024-15216.
   PubMed    
   
   
   
7. LEE TS, Li I, Peric B, Saw RPM, et al
   Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective, Randomised Trial.
   Ann Surg Oncol. 2024 Mar 17. doi: 10.1245/s10434-024-15149.
   PubMed     Abstract available
   
   
   February 2024
8. MENSAH JA, Fei-Zhang DJ, Rossen JL, Rahmani B, et al
   Assessment of Social Vulnerabilities of Care and Prognosis in Adult Ocular Melanomas in the US.
   Ann Surg Oncol. 2024 Feb 28. doi: 10.1245/s10434-024-15038.
   PubMed     Abstract available
   
   
   
9. MADDINENI S, Dizon MP, Muralidharan V, Young LA, et al
   ASO Visual Abstract: Validation of the Melanoma Institute of Australia's Sentinel Lymph Node Biopsy Risk Prediction Tool for Cutaneous Melanoma.
   Ann Surg Oncol. 2024 Feb 5. doi: 10.1245/s10434-024-14996.
   PubMed    
   
   
   
10. DEDEILIA A, Lwin T, Li S, Tarantino G, et al
    ASO Visual Abstract: Factors Affecting Recurrence and Survival in High-Risk Stage II Melanoma.
    Ann Surg Oncol. 2024 Feb 1. doi: 10.1245/s10434-023-14869.
    PubMed    
    
    
    January 2024
11. ROSHAN A, Shah B, Anderson KD, Murphy S, et al
    ASO Visual Abstract: Robot-Assisted Pelvic Dissection for Enlarged Lymph Nodes in Melanoma Improves Recovery with Equivalent Oncological Outcomes to Open Pelvic Dissection.
    Ann Surg Oncol. 2024 Jan 22. doi: 10.1245/s10434-024-14920.
    PubMed    
    
    
    
12. MADDINENI S, Dizon MP, Muralidharan V, Young LA, et al
    Validation of the Melanoma Institute of Australia's Sentinel Lymph Node Biopsy Risk Prediction Tool for Cutaneous Melanoma.
    Ann Surg Oncol. 2024 Jan 12. doi: 10.1245/s10434-023-14862.
    PubMed     Abstract available
    
    
    
13. ROSHAN A, Shah B, Anderson KD, Murphy S, et al
    Robot-Assisted Pelvic Dissection for Enlarged Lymph Nodes in Melanoma Improves Recovery with Equivalent Oncological Outcomes to Open Pelvic Dissection.
    Ann Surg Oncol. 2024 Jan 4. doi: 10.1245/s10434-023-14834.
    PubMed     Abstract available
    
    
    December 2023
14. DEDEILIA A, Lwin T, Li S, Tarantino G, et al
    Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma.
    Ann Surg Oncol. 2023 Dec 29. doi: 10.1245/s10434-023-14724.
    PubMed     Abstract available
    
    
    
15. GJORUP CA, Woodford R, Li I, Carlino MS, et al
    ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging.
    Ann Surg Oncol. 2023 Dec 20. doi: 10.1245/s10434-023-14665.
    PubMed    
    
    
    
16. BEASLEY GM, Terando AM
    Articles from 2022 to 2023 to Inform Your Cancer Practice: Melanoma.
    Ann Surg Oncol. 2023 Dec 10. doi: 10.1245/s10434-023-14702.
    PubMed     Abstract available
    
    
    
17. GJORUP CA, van Akkooi ACJ
    ASO Author Reflections: Recurrence in Sentinel Node-Positive Node Fields in Melanoma Patients Undergoing Surveillance Is More Common outside the Node Field.
    Ann Surg Oncol. 2023 Dec 4. doi: 10.1245/s10434-023-14623.
    PubMed    
    
    
    November 2023
18. SU D, Kluger H, Olino K
    Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma.
    Ann Surg Oncol. 2023 Nov 21. doi: 10.1245/s10434-023-14587.
    PubMed     Abstract available
    
    
    
19. GJORUP CA, Woodford R, Li I, Carlino MS, et al
    Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging.
    Ann Surg Oncol. 2023 Nov 15. doi: 10.1245/s10434-023-14526.
    PubMed     Abstract available
    
    
    October 2023
20. VAN AKKOOI ACJ
    Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?
    Ann Surg Oncol. 2023 Oct 16. doi: 10.1245/s10434-023-14416.
    PubMed    
    
    
    September 2023
21. HOLDER AM, Wargo JA, Ross MI
    Correction: Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma.
    Ann Surg Oncol. 2023 Sep 3. doi: 10.1245/s10434-023-14252.
    PubMed    
    
    
    August 2023
22. KESMODEL SB, Kronenfeld JP, Zhao W, Koru-Sengul T, et al
    ASO Visual Abstract: Omission of Completion Lymph Node Dissection in Sentinel Node Biopsy Positive Head and Neck Cutaneous Melanoma Patients.
    Ann Surg Oncol. 2023 Aug 31. doi: 10.1245/s10434-023-14183.
    PubMed    
    
    
    
23. KESMODEL SB, Kronenfeld JP, Zhao W, Koru-Sengul T, et al
    Omission of Completion Lymph Node Dissection in Sentinel Node Biopsy Positive Head and Neck Cutaneous Melanoma Patients.
    Ann Surg Oncol. 2023 Aug 28. doi: 10.1245/s10434-023-14036.
    PubMed     Abstract available
    
    
    
24. HOLMBERG CJ, Mikiver R, Isaksson K, Ingvar C, et al
    ASO Visual Abstract: Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (> 4 mm).
    Ann Surg Oncol. 2023 Aug 21. doi: 10.1245/s10434-023-14106.
    PubMed    
    
    
    
25. HOLDER AM, Wargo JA, Ross MI
    Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma.
    Ann Surg Oncol. 2023 Aug 19. doi: 10.1245/s10434-023-14133.
    PubMed    
    
    
    
26. SKITZKI JJ
    The Argument for Performing Sentinel Lymph Node Biopsy in Thick Primary Melanomas.
    Ann Surg Oncol. 2023 Aug 17. doi: 10.1245/s10434-023-14148.
    PubMed    
    
    
    
27. RHODIN KE, Jung SH, Elleson K, DePalo D, et al
    ASO Visual Abstract: Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does It Matter?
    Ann Surg Oncol. 2023 Aug 14. doi: 10.1245/s10434-023-14089.
    PubMed    
    
    
    
28. HOLMBERG CJ, Mikiver R, Isaksson K, Ingvar C, et al
    Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (> 4 mm).
    Ann Surg Oncol. 2023 Aug 14. doi: 10.1245/s10434-023-14050.
    PubMed     Abstract available
    
    
    
29. BATENI SB, Sutradhar R, Everett K, Wright FC, et al
    ASO Visual Abstract: The Association Between Pregnancy Timing and Cumulative Exposure on Survival in Melanoma.
    Ann Surg Oncol. 2023 Aug 5. doi: 10.1245/s10434-023-13995.
    PubMed    
    
    
    July 2023
30. GERSHENWALD JE
    Top Melanoma Articles from 2021 to Inform Your Cancer Practice.
    Ann Surg Oncol. 2023 Jul 26. doi: 10.1245/s10434-023-13853.
    PubMed     Abstract available
    
    
    
31. RHODIN KE, Jung SH, Elleson K, DePalo D, et al
    Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?
    Ann Surg Oncol. 2023 Jul 22. doi: 10.1245/s10434-023-13935.
    PubMed     Abstract available
    
    
    
32. RHODIN KE, Tyler DS, Zager JS, Beasley GM, et al
    Great Debate: Limb Infusion for Melanoma: A Thing of the Past?
    Ann Surg Oncol. 2023 Jul 17. doi: 10.1245/s10434-023-13765.
    PubMed    
    
    
    
33. PRIETO PA, Goldberg MS, Martin B
    RE: A Clinical Decision Tool to Calculate Pretest Probability of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
    Ann Surg Oncol. 2023 Jul 3. doi: 10.1245/s10434-023-13812.
    PubMed    
    
    
    June 2023
34. BATENI SB, Sutradhar R, Everett K, Wright FC, et al
    The Association Between Pregnancy Timing and Cumulative Exposure on Survival in Melanoma.
    Ann Surg Oncol. 2023 Jun 29. doi: 10.1245/s10434-023-13819.
    PubMed     Abstract available
    
    
    
35. TRIPATHI R, Larson K, Fowler G, Vetto JT, et al
    The Role of Clinicopathologic Nomograms for Melanoma in the Era of Gene Expression Profiling.
    Ann Surg Oncol. 2023 Jun 27. doi: 10.1245/s10434-023-13814.
    PubMed    
    
    
    
36. SHARON CE, Tortorello GN, Ma K, Sinnamon AJ, et al
    Impact of Adjuvant Immunotherapy on Overall Survival in a Contemporary Cohort of Patients with Stage III Melanoma.
    Ann Surg Oncol. 2023 Jun 19. doi: 10.1245/s10434-023-13736.
    PubMed    
    
    
    
37. FARIES MB, Lowe M
    Metastasectomy in Stage IV Melanoma: How and When Should We Employ It?
    Ann Surg Oncol. 2023 Jun 16. doi: 10.1245/s10434-023-13760.
    PubMed    
    
    
    
38. MONTGOMERY KB, Holder AM, Burgan CM, Galgano SJ, et al
    Is it Time for Synoptic Reporting in Melanoma Nodal Surveillance Ultrasonography?
    Ann Surg Oncol. 2023 Jun 16. doi: 10.1245/s10434-023-13749.
    PubMed    
    
    
    May 2023
39. LWIN TM, Kaelberer Z, Ruan M, Molina G, et al
    ASO Visual Abstract: Surgical Utilization and Outcomes for Patients with Stage 4 Melanoma in the Modern Immunotherapy Era.
    Ann Surg Oncol. 2023 May 29. doi: 10.1245/s10434-023-13611.
    PubMed    
    
    
    
40. LWIN T, Molina G, Boland G
    ASO Author Reflections: The Evolution of Surgery for Patients with Stage IV Melanoma.
    Ann Surg Oncol. 2023 May 24. doi: 10.1245/s10434-023-13646.
    PubMed     Abstract available
    
    
    
41. ESSNER R, Keller J
    Regarding: "Predicting Regional Lymph Node Recurrence in the Modern Age of Tumor-Positive Sentinel Node Melanoma," by Faries, Mark et al.
    Ann Surg Oncol. 2023 May 12. doi: 10.1245/s10434-023-13573.
    PubMed    
    
    
    
42. THOMPSON JF, Hyngstrom J, Caraco C, Zager JS, et al
    Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma.
    Ann Surg Oncol. 2023 May 6. doi: 10.1245/s10434-023-13570.
    PubMed    
    
    
    
43. SCHOENFELDT T, Chakera AH, Nieweg OE, Thompson JF, et al
    ASO Author Reflections: The Clinical Relevance of Sentinel Nodes in Minor Lymph Node Fields Such as the Triangular Intermuscular Space in Patients with Melanoma.
    Ann Surg Oncol. 2023 May 3. doi: 10.1245/s10434-023-13443.
    PubMed    
    
    
    
44. LWIN TM, Kaelberer Z, Ruan M, Molina G, et al
    Surgical Utilization and Outcomes for Patients with Stage IV Melanoma in the Modern Immunotherapy Era.
    Ann Surg Oncol. 2023 May 1. doi: 10.1245/s10434-023-13543.
    PubMed     Abstract available
    
    
    April 2023
45. GREENE AC, Wong WG, Perez Holguin RA, Patel A, et al
    ASO Visual Abstract: The Association of Guideline-Concordant Sentinel Lymph Node Biopsy for Melanoma at Minority-Serving Hospitals.
    Ann Surg Oncol. 2023 Apr 28. doi: 10.1245/s10434-023-13491.
    PubMed    
    
    
    
46. FADEL MG, Rauf S, Mohamed HS, Yusuf S, et al
    ASO Visual Abstract: The Use of Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye in Sentinel Lymph Node Biopsy in Cutaneous Melanoma: A Retrospective, Cohort Study.
    Ann Surg Oncol. 2023 Apr 21. doi: 10.1245/s10434-023-13479.
    PubMed    
    
    
    
47. FADEL MG, Rauf S, Mohamed HS, Yusuf S, et al
    The Use of Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye in Sentinel Lymph Node Biopsy in Cutaneous Melanoma: A Retrospective, Cohort Study.
    Ann Surg Oncol. 2023 Apr 16. doi: 10.1245/s10434-023-13405.
    PubMed     Abstract available
    
    
    
48. TRIPATHI R, Larson K, Fowler G, Han D, et al
    ASO Visual Abstract: A Clinical Decision Tool to Calculate Pretest Probability of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
    Ann Surg Oncol. 2023 Apr 15. doi: 10.1245/s10434-023-13410.
    PubMed    
    
    
    
49. SENDERS ZJ, Bartlett EK, Mouw TJ, McMasters KM, et al
    ASO Visual Abstract: Does Stage Migration Occur as a Consequence of Omitting Completion Lymph Node Dissection for Melanoma?
    Ann Surg Oncol. 2023 Apr 12. doi: 10.1245/s10434-023-13439.
    PubMed    
    
    
    
50. FADEL MG, Smith MJ
    ASO Author Reflections: Comparison of Indocyanine Green with Blue Dye in Sentinel Lymph Node Biopsy for Cutaneous Melanoma.
    Ann Surg Oncol. 2023 Apr 4. doi: 10.1245/s10434-023-13423.
    PubMed    
    
    
    March 2023
51. GREENE AC, Wong WG, Pameijer CR, Shen C, et al
    ASO Author Reflections: Lower Guideline Concordance and Decreased Overall Survival for Melanoma Patients at Minority-Serving Hospitals: How Can We Do Better?
    Ann Surg Oncol. 2023 Mar 30. doi: 10.1245/s10434-023-13377.
    PubMed    
    
    
    
52. GREENE AC, Wong WG, Perez Holguin RA, Patel A, et al
    The Association of Guideline-Concordant Sentinel Lymph Node Biopsy for Melanoma at Minority-Serving Hospitals.
    Ann Surg Oncol. 2023 Mar 19. doi: 10.1245/s10434-023-13341.
    PubMed     Abstract available
    
    
    
53. SENDERS ZJ, Bartlett EK, Mouw TJ, McMasters KM, et al
    Does Stage Migration Occur as a Consequence of Omitting Completion Lymph Node Dissection for Melanoma?
    Ann Surg Oncol. 2023 Mar 19. doi: 10.1245/s10434-023-13342.
    PubMed     Abstract available
    
    
    
54. ZAGER JS, van Akkooi ACJ
    Talimogene Laherparepvec in Combination with Immunotherapy, A Viable Option?
    Ann Surg Oncol. 2023;30:1279-1281.
    PubMed    
    
    
    February 2023
55. TRIPATHI R, Larson K, Fowler G, Han D, et al
    A Clinical Decision Tool to Calculate Pretest Probability of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
    Ann Surg Oncol. 2023 Feb 25:1-8. doi: 10.1245/s10434-023-13220.
    PubMed     Abstract available
    
    
    
56. TRIPATHI R, Larson K, Fowler G, Han D, et al
    ASO Author Reflections: Using Big Data to Bring Precision Medicine to Melanoma Management.
    Ann Surg Oncol. 2023 Feb 23. doi: 10.1245/s10434-023-13268.
    PubMed    
    
    
    
57. FARIES MB, Karakousis G
    Commentary re PRADO: De-escalation in Melanoma After Neoadjuvant Therapy: When to Cut and When to Cut Back.
    Ann Surg Oncol. 2023 Feb 22. doi: 10.1245/s10434-023-13251.
    PubMed    
    
    
    
58. KELLER J, Stern S, Chang SC, Marcus R, et al
    Correction: Predicting Regional Lymph Node Recurrence in the Modern Age of Tumor-Positive Sentinel Node Melanoma: The Role of the First Postoperative Ultrasound.
    Ann Surg Oncol. 2023 Feb 17. doi: 10.1245/s10434-023-13186.
    PubMed    
    
    
    
59. RUTKOWSKI P, Kosela-Paterczyk H
    Perioperative Therapy in Melanoma: Several Questions Still Remain.
    Ann Surg Oncol. 2023 Feb 10. doi: 10.1245/s10434-023-13107.
    PubMed    
    
    
    
60. HELVIND NM, Weitemeyer MB, Chakera AH, Hendel HW, et al
    Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients.
    Ann Surg Oncol. 2023 Feb 8. doi: 10.1245/s10434-022-13034.
    PubMed     Abstract available
    
    
    
61. JEREMIASSE B, van Scheltinga CEJT, Smeele LE, Tolboom N, et al
    ASO Visual Abstract: Sentinel Lymph Node Procedure in Pediatric Patients with Melanoma, Squamous Cell Carcinoma or Sarcoma Using Near-Infrared Fluorescence Imaging with Indocyanine Green: A Feasibility Trial.
    Ann Surg Oncol. 2023 Feb 6. doi: 10.1245/s10434-022-13071.
    PubMed    
    
    
    January 2023
62. HELVIND NM, Weitemeyer MB, Chakera AH, Hendel HW, et al
    ASO Visual Abstract: Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma-A National Cohort Study of 1480 Patients.
    Ann Surg Oncol. 2023 Jan 30. doi: 10.1245/s10434-022-13082.
    PubMed    
    
    
    
63. COHEN S, Tanabe KK
    Adjuvant Systemic Therapy for High-Risk Melanoma.
    Ann Surg Oncol. 2023 Jan 20. doi: 10.1245/s10434-023-13105.
    PubMed    
    
    
    
64. SHARON CE, Tortorello GN, Gimotty PA, Beasley GM, et al
    Outcomes of Single Node Excision Compared with Lymph Node Dissection for Patients with Clinical Stage III N1b Cutaneous Melanoma.
    Ann Surg Oncol. 2023 Jan 16. doi: 10.1245/s10434-022-12999.
    PubMed    
    
    
    
65. JEREMIASSE B, van Scheltinga CEJT, Smeele LE, Tolboom N, et al
    Sentinel Lymph Node Procedure in Pediatric Patients with Melanoma, Squamous Cell Carcinoma, or Sarcoma Using Near-Infrared Fluorescence Imaging with Indocyanine Green: A Feasibility Trial.
    Ann Surg Oncol. 2023 Jan 15. doi: 10.1245/s10434-022-12978.
    PubMed     Abstract available
    
    
    
66. RHODIN KE, Farrow NE, Xu M, Lee J, et al
    National Trends in Management of Pathologic Stage III Melanoma.
    Ann Surg Oncol. 2023 Jan 15. doi: 10.1245/s10434-023-13101.
    PubMed    
    
    
    
67. XIA TY, Cakmakoglu C, Kwiecien GJ, Gastman BR, et al
    ASO Visual Abstract: Prophylactic Lymphaticovenous Anastomosis Performed with Lymphadenectomy is Oncologically Safe for Melanoma.
    Ann Surg Oncol. 2023 Jan 10. doi: 10.1245/s10434-022-12855.
    PubMed    
    
    
    
68. XIA T, Cakmakoglu C, Kwiecien G, Gastman B, et al
    ASO Author Reflections: Prophylactic Lymphaticovenous Anastomosis Performed with Lymphadenectomy is Oncologically Safe for Melanoma.
    Ann Surg Oncol. 2023 Jan 4. doi: 10.1245/s10434-022-12874.
    PubMed    
    
    
    December 2022
69. HUSSAIN Z, Moncrieff M
    ASO Author Reflections: Risk Stratification of Sentinel Node Metastases in Stage III Melanoma Patients in the Era of Adjuvant Systemic Therapy.
    Ann Surg Oncol. 2022 Dec 20. doi: 10.1245/s10434-022-12847.
    PubMed    
    
    
    
70. PEREZ-MORALES J, Broman KK, Bettampadi D, Haver MK, et al
    ASO Visual Abstract: Recurrence Patterns for Regionally Metastatic Melanoma Treated in the Era of Adjuvant Therapy: A Systematic Review and Meta-Analysis.
    Ann Surg Oncol. 2022 Dec 20. doi: 10.1245/s10434-022-12929.
    PubMed    
    
    
    
71. SCHOENFELDT T, Thompson JF, Lo S, Drzewiecki KT, et al
    ASO Visual Abstract: Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma.
    Ann Surg Oncol. 2022 Dec 16. doi: 10.1245/s10434-022-12889.
    PubMed    
    
    
    
72. PEREZ-MORALES J, Broman KK, Bettampadi D, Haver MK, et al
    Recurrence Patterns for Regionally Metastatic Melanoma Treated in the Era of Adjuvant Therapy: A Systematic Review and Meta-Analysis.
    Ann Surg Oncol. 2022 Dec 7. doi: 10.1245/s10434-022-12866.
    PubMed     Abstract available
    
    
    
73. XIA TY, Cakmakoglu C, Kwiecien GJ, Gastman BR, et al
    Prophylactic Lymphaticovenous Anastomosis Performed with Lymphadenectomy is Oncologically Safe for Melanoma.
    Ann Surg Oncol. 2022 Dec 5. doi: 10.1245/s10434-022-12791.
    PubMed     Abstract available
    
    
    
74. SCHOENFELDT T, Thompson JF, Lo S, Drzewiecki KT, et al
    Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma.
    Ann Surg Oncol. 2022 Dec 3. doi: 10.1245/s10434-022-12840.
    PubMed     Abstract available
    
    
    November 2022
75. HUSSAIN Z, Heaton MJ, Snelling AP, Nobes JP, et al
    ASO Visual Abstract: Risk Stratification of Sentinel Node Metastasis Disease Burden and Phenotype in Stage III Melanoma Patients.
    Ann Surg Oncol. 2022 Nov 29. doi: 10.1245/s10434-022-12859.
    PubMed    
    
    
    
76. HUSSAIN Z, Heaton MJ, Snelling AP, Nobes JP, et al
    Risk Stratification of Sentinel Node Metastasis Disease Burden and Phenotype in Stage III Melanoma Patients.
    Ann Surg Oncol. 2022 Nov 29. doi: 10.1245/s10434-022-12804.
    PubMed     Abstract available
    
    
    
77. CASTLE JT, Adatorwovor R, Levy BE, Marcinkowski EF, et al
    ASO Visual Abstract: Completion Lymph Node Dissection for Melanoma Before and After the Multicenter Selective Lymphadenectomy Trial-II in the USA.
    Ann Surg Oncol. 2022 Nov 22. doi: 10.1245/s10434-022-12815.
    PubMed    
    
    
    
78. CASTLE JT, Adatorwovor R, Levy BE, Marcinkowski EF, et al
    Completion Lymph Node Dissection for Melanoma Before and After the Multicenter Selective Lymphadenectomy Trial-II in the United States.
    Ann Surg Oncol. 2022 Nov 4. pii: 10.1245/s10434-022-12745.
    PubMed     Abstract available
    
    
    
79. BLANKENSTEIN SA, Bonenkamp JJ, Aarts MJB, van den Berkmortel FWPJ, et al
    ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
    Ann Surg Oncol. 2022 Nov 1. pii: 10.1245/s10434-022-12719.
    PubMed    
    
    
    October 2022
80. PARVEZ E, Khosrow-Khavar F, Dumitra T, Nessim C, et al
    Multicenter Adoption and Outcomes of Nodal Observation for Patients with Melanoma and Sentinel Lymph Node Metastases.
    Ann Surg Oncol. 2022 Oct 25. pii: 10.1245/s10434-022-12695.
    PubMed     Abstract available
    
    
    
81. GUO J, Balch CM
    Letter to the Editor Concerning "An Evidence-Based Staging System for Mucosal Melanoma: A Proposal," by Smith, Henry et al.
    Ann Surg Oncol. 2022 Oct 18. pii: 10.1245/s10434-022-12635.
    PubMed    
    
    
    
82. BLANKENSTEIN SA, Bonenkamp JJ, Aarts MJB, van den Berkmortel FWPJ, et al
    Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
    Ann Surg Oncol. 2022 Oct 6. pii: 10.1245/s10434-022-12600.
    PubMed     Abstract available
    
    
    September 2022
83. SMITH HG, Harrington KJ, Smith MJF
    Letter to the Editor Regarding "An Evidence-Based Staging System for Mucosal Melanoma: A Proposal".
    Ann Surg Oncol. 2022 Sep 29. pii: 10.1245/s10434-022-12631.
    PubMed    
    
    
    
84. KOORAGAYALA K, Lou J, Hong YK
    ASO Author Reflections: Commercialization of Adaptive Cell Therapy for Metastatic Melanoma.
    Ann Surg Oncol. 2022 Sep 26. pii: 10.1245/s10434-022-12588.
    PubMed    
    
    
    
85. DE RAVIN E, Suresh N, Romeo D, Lu J, et al
    Clinical Practice Guidelines on Sentinel Lymph Node Biopsy for Melanoma: A Systematic Review and Quality Appraisal Using the AGREE II Instrument.
    Ann Surg Oncol. 2022 Sep 19. pii: 10.1245/s10434-022-12525.
    PubMed     Abstract available
    
    
    
86. KOORAGAYALA K, Lou J, Hong YK
    Adoptive Cellular Therapy for Metastatic Melanoma: The Road to Commercialization and Treatment Guidelines for Clinicians.
    Ann Surg Oncol. 2022 Sep 16. pii: 10.1245/s10434-022-12528.
    PubMed     Abstract available
    
    
    
87. KELLER J, Stern S, Chang SC, Marcus R, et al
    ASO Visual Abstract: Predicting Regional Lymph Node Recurrence in the Modern Age of Tumor-Positive Sentinel Node Melanoma: The Role of the First Postoperative Ultrasound.
    Ann Surg Oncol. 2022 Sep 4. pii: 10.1245/s10434-022-12402.
    PubMed    
    
    
    August 2022
88. SHARON CE, Straker RJ 3rd, Li EH, Karakousis GC, et al
    National Practice Patterns in the Management of the Regional Lymph Node Basin After Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma.
    Ann Surg Oncol. 2022 Aug 25. pii: 10.1245/s10434-022-12364.
    PubMed     Abstract available
    
    
    
89. LAWLESS AK, Coker DJ, Lo SN, Ahmed T, et al
    ASO Visual Abstract: Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-transit Melanoma Metastases.
    Ann Surg Oncol. 2022 Aug 22. pii: 10.1245/s10434-022-12266.
    PubMed    
    
    
    
90. SHARON CE, Straker RJ 3rd, Li E, Karakousis GC, et al
    ASO Visual Abstract: National Practice Patterns in the Management of the Regional Lymph Node Basin Following Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma.
    Ann Surg Oncol. 2022 Aug 21. pii: 10.1245/s10434-022-12452.
    PubMed    
    
    
    
91. KELLER J, Stern S, Chang SC, Marcus R, et al
    Predicting Regional Lymph Node Recurrence in the Modern Age of Tumor-Positive Sentinel Node Melanoma: The Role of the First Postoperative Ultrasound.
    Ann Surg Oncol. 2022 Aug 21. pii: 10.1245/s10434-022-12345.
    PubMed     Abstract available
    
    
    
92. RAMTOHUL T, Abdul-Baki M, Rodrigues M, Cassoux N, et al
    Tumor Growth Rate as a Predictive Marker for Recurrence and Survival After Liver Resection in Patients with Liver Metastases of Uveal Melanoma.
    Ann Surg Oncol. 2022 Aug 18. pii: 10.1245/s10434-022-12368.
    PubMed     Abstract available
    
    
    
93. SHARON CE, Karakousis GC, Miura JT
    ASO Author Reflections: Management of the Lymph Node Basin in Cutaneous Melanoma-Patterns of Completion Dissection in a National Cohort.
    Ann Surg Oncol. 2022 Aug 6. pii: 10.1245/s10434-022-12373.
    PubMed    
    
    
    July 2022
94. SHARON CE, Karakousis GC
    ASO Author Reflections: Neoadjuvant Treatment for Melanoma-Where Are We Now?
    Ann Surg Oncol. 2022 Jul 26. pii: 10.1245/s10434-022-12308.
    PubMed    
    
    
    
95. LAWLESS AK, Coker DJ, Saw RPM
    ASO Author Reflections: What Is the Role of Surgery in Management of In-Transit Melanoma in the Modern Era?
    Ann Surg Oncol. 2022 Jul 19. pii: 10.1245/s10434-022-12188.
    PubMed    
    
    
    
96. SHARON CE, Karakousis GC
    Educational Review: Neoadjuvant Approaches to Melanoma.
    Ann Surg Oncol. 2022 Jul 18. pii: 10.1245/s10434-022-12224.
    PubMed     Abstract available
    
    
    
97. WALKER RJB, Look Hong NJ, Moncrieff M, van Akkooi ACJ, et al
    ASO Visual Abstract: Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma-An International Multi-institutional Collaboration.
    Ann Surg Oncol. 2022 Jul 9. pii: 10.1245/s10434-022-12050.
    PubMed    
    
    
    June 2022
98. LAWLESS AK, Coker DJ, Lo SN, Ahmed T, et al
    Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases.
    Ann Surg Oncol. 2022 Jun 30. pii: 10.1245/s10434-022-11997.
    PubMed     Abstract available
    
    
    
99. WALKER RJB, Look Hong NJ, Moncrieff M, van Akkooi ACJ, et al
    Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration.
    Ann Surg Oncol. 2022 Jun 8. pii: 10.1245/s10434-022-11936.
    PubMed     Abstract available
    
    
    
100. TEKE ME, Rossi AJ, Hernandez JM, Gastman B, et al
     Pembrolizumab Compared with Standard-of-Care Observation in Treating Patients with Completely Resected Stage I-III Merkel Cell Cancer (STAMP).
     Ann Surg Oncol. 2022;29:3379-3380.
     PubMed    
     
     
     
101. MONCRIEFF MD, Thompson JF
     Evaluating and Embracing Modern Imaging Technology to Guide Sentinel Node Biopsy for Melanoma.
     Ann Surg Oncol. 2022 Jun 1. pii: 10.1245/s10434-022-11935.
     PubMed    
     
     
     May 2022
102. BARTLETT EK, Grossman D, Swetter SM, Leachman SA, et al
     ASO Visual Abstract: Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts.
     Ann Surg Oncol. 2022 May 26. pii: 10.1245/s10434-022-11903.
     PubMed    
     
     
     
103. MONTGOMERY KB, Correya TA, Broman KK
     ASO Visual Abstract: Real-World Adherence to Nodal Surveillance for Sentinel Lymph Node-Positive Melanoma.
     Ann Surg Oncol. 2022 May 25. pii: 10.1245/s10434-022-11902.
     PubMed    
     
     
     
104. MONCRIEFF MD, Lo SN, Scolyer RA, Heaton MJ, et al
     ASO Visual Abstract: Evaluation of Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International Multicenter Study.
     Ann Surg Oncol. 2022 May 25. pii: 10.1245/s10434-022-11822.
     PubMed    
     
     
     
105. MONTGOMERY KB, Correya TA, Broman KK
     Real-World Adherence to Nodal Surveillance for Sentinel Lymph Node-Positive Melanoma.
     Ann Surg Oncol. 2022 May 24. pii: 10.1245/s10434-022-11839.
     PubMed     Abstract available
     
     
     
106. BARTLETT EK, Grossman D, Swetter SM, Leachman SA, et al
     Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts.
     Ann Surg Oncol. 2022 May 18. pii: 10.1245/s10434-022-11869.
     PubMed     Abstract available
     
     
     
107. CUI C, Lian B, Zhang X, Wu D, et al
     ASO Visual Abstract: An Evidence-Based Staging System for Mucosal Melanoma: a Proposal.
     Ann Surg Oncol. 2022 May 17. pii: 10.1245/s10434-022-11786.
     PubMed    
     
     
     
108. MONCRIEFF MD, Lo SN, Scolyer RA, Heaton MJ, et al
     Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study.
     Ann Surg Oncol. 2022 May 13. pii: 10.1245/s10434-022-11761.
     PubMed     Abstract available
     
     
     
109. JAKUB JW, Lowe M, Harrison Howard J, Farma JM, et al
     ASO Visual Abstract: Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in MSLT-II.
     Ann Surg Oncol. 2022 May 12. pii: 10.1245/s10434-022-11856.
     PubMed    
     
     
     
110. WIENER AA, Schumacher JR, Racz JM, Weber SM, et al
     ASO Visual Abstract: Incidence of Second Primary Melanoma in Survivors of Cutaneous Melanoma.
     Ann Surg Oncol. 2022 May 11. pii: 10.1245/s10434-022-11852.
     PubMed    
     
     
     
111. MONTGOMERY KB, Broman KK
     ASO Author Reflections: Challenges to Achieving Consistent Nodal Surveillance with Ultrasound in Melanoma.
     Ann Surg Oncol. 2022 May 9. pii: 10.1245/s10434-022-11883.
     PubMed    
     
     
     
112. BARTLETT EK, Marchetti MA
     ASO Author Reflections: Why Treatment Risk Thresholds Are Needed for Patients with Melanoma.
     Ann Surg Oncol. 2022 May 6. pii: 10.1245/s10434-022-11884.
     PubMed    
     
     
     
113. WIENER AA, Schumacher JR, Neuman HB
     ASO Author Reflections: Counseling Melanoma Survivors on the Risk of a Second Melanoma.
     Ann Surg Oncol. 2022 May 6. pii: 10.1245/s10434-022-11748.
     PubMed    
     
     
     
114. WIENER AA, Schumacher JR, Racz JM, Weber SM, et al
     Incidence of Second Primary Melanoma in Cutaneous Melanoma Survivors.
     Ann Surg Oncol. 2022 May 3. pii: 10.1245/s10434-022-11725.
     PubMed     Abstract available
     
     
     
115. JAKUB JW, Lowe M, Howard JH, Farma JM, et al
     Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II).
     Ann Surg Oncol. 2022 May 2. pii: 10.1245/s10434-022-11758.
     PubMed     Abstract available
     
     
     April 2022
116. JAKUB JW, Faries MB
     ASO Author Reflections: Minimally Invasive Inguinal Lymphadenectomy, an Incremental Step in the Evolution of the Management of Advanced Melanoma.
     Ann Surg Oncol. 2022 Apr 30. pii: 10.1245/s10434-022-11847.
     PubMed    
     
     
     
117. ROSSI AJ, Verbus EA, Faries MB, Moncrieff M, et al
     A Phase III, Multicenter, Randomized Controlled Trial Investigating 1-cm Versus 2-cm Surgical Excision Margins for Stage II Primary Cutaneous Melanoma (MelMarT-II).
     Ann Surg Oncol. 2022 Apr 22. pii: 10.1245/s10434-022-11766.
     PubMed    
     
     
     
118. GYORKI DE
     Spoiled for Choice: Do We Finally Have Clarity on Optimal Treatment Sequencing for Patients with Metastatic Melanoma Harboring an Actionable BRAF Mutation?
     Ann Surg Oncol. 2022 Apr 16. pii: 10.1245/s10434-022-11611.
     PubMed    
     
     
     
119. VAN AKKOOI ACJ, Hieken TJ, Burton EM, Ariyan C, et al
     Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).
     Ann Surg Oncol. 2022 Apr 15. pii: 10.1245/s10434-022-11622.
     PubMed    
     
     
     
120. CUI C, Lian B, Guo J
     ASO Author Reflections: Staging System for Mucosal Melanoma: A Proposal to Fill a Gap.
     Ann Surg Oncol. 2022 Apr 12. pii: 10.1245/s10434-022-11746.
     PubMed    
     
     
     
121. CUI C, Lian B, Zhang X, Wu D, et al
     An Evidence-Based Staging System for Mucosal Melanoma: A Proposal.
     Ann Surg Oncol. 2022 Apr 9. pii: 10.1245/s10434-022-11670.
     PubMed     Abstract available
     
     
     
122. COOK RW, Goldberg MS
     Comments on Post-Publication Discussion of "Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma".
     Ann Surg Oncol. 2022 Apr 5. pii: 10.1245/s10434-022-11651.
     PubMed    
     
     
     March 2022
123. STRAKER RJ 3RD, Krupp K, Sharon CE, Thaler AS, et al
     ASO Visual Abstract: Prognostic Significance of Primary-Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort.
     Ann Surg Oncol. 2022 Mar 22. pii: 10.1245/s10434-022-11566.
     PubMed    
     
     
     
124. STRAKER RJ 3RD, Krupp K, Karakousis GC
     ASO Author Reflections: Prognostic Significance of Primary Tumor Infiltrating Lymphocytes in the Contemporary Melanoma Era.
     Ann Surg Oncol. 2022 Mar 18. pii: 10.1245/s10434-022-11519.
     PubMed    
     
     
     
125. STRAKER RJ 3RD, Krupp K, Sharon CE, Thaler AS, et al
     Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort.
     Ann Surg Oncol. 2022 Mar 17. pii: 10.1245/s10434-022-11478.
     PubMed     Abstract available
     
     
     
126. STRAKER RJ 3RD, Tidwell JC, Sharon CE, Chu EY, et al
     Association Between Underlying Comorbid Conditions and Stage of Presentation in Cutaneous Melanoma.
     Ann Surg Oncol. 2022 Mar 16. pii: 10.1245/s10434-022-11547.
     PubMed    
     
     
     
127. STAHLIE EHA, Carr MJ, Zager JS, van Akkooi ACJ, et al
     External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort.
     Ann Surg Oncol. 2022;29:1637-1644.
     PubMed     Abstract available
     
     
     February 2022
128. SAIF A, Rossi AJ, Sarnaik A, Hernandez JM, et al
     Efficacy of Neoadjuvant Intratumoral Darleukin/Fibromun (L19IL2 + L19TNF) in Patients with Clinical Stage IIIB/C Melanoma (Neo-DREAM).
     Ann Surg Oncol. 2022 Feb 28. pii: 10.1245/s10434-022-11447.
     PubMed    
     
     
     
129. WANKHEDE D, Grover S
     ASO Visual Abstract: Outcomes Following Curative Metastasectomy for Patients with Malignant Melanoma: A Systematic Review and Meta-Analysis.
     Ann Surg Oncol. 2022 Feb 21. pii: 10.1245/s10434-022-11391.
     PubMed    
     
     
     
130. DIENG M, Lord SJ, Turner RM, Nieweg OE, et al
     The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma.
     Ann Surg Oncol. 2022 Feb 10. pii: 10.1245/s10434-021-11231.
     PubMed     Abstract available
     
     
     
131. WANKHEDE D, Grover S
     Outcomes After Curative Metastasectomy for Patients with Malignant Melanoma: A Systematic Review and Meta-analysis.
     Ann Surg Oncol. 2022 Feb 6. pii: 10.1245/s10434-022-11351.
     PubMed     Abstract available
     
     
     January 2022
132. VAN AKKOOI ACJ, Hieken TJ, Burton EM, Ariyan C, et al
     Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).
     Ann Surg Oncol. 2022 Jan 28. pii: 10.1245/s10434-021-11236.
     PubMed     Abstract available
     
     
     
133. MORRISON S, Han G, Elenwa F, Vetto JT, et al
     Is There a Relationship Between TILs and Regression in Melanoma?
     Ann Surg Oncol. 2022 Jan 21. pii: 10.1245/s10434-021-11251.
     PubMed     Abstract available
     
     
     
134. KHAN TM, Teke ME, Karakousis GC, Miura JT, et al
     Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab.
     Ann Surg Oncol. 2022 Jan 21. pii: 10.1245/s10434-021-11199.
     PubMed    
     
     
     
135. MORRISON S, Zager JS, Vetto J
     ASO Author Reflections: Is There a Relationship Between TIL and Regression in Melanoma?
     Ann Surg Oncol. 2022 Jan 21. pii: 10.1245/s10434-021-11264.
     PubMed    
     
     
     
136. MORRISON S, Han G, Elenwa F, Vetto J, et al
     ASO Visual Abstract: Is There a Relationship Between Tumor-Infiltrating Lymphocytes (TILs) and Regression in Melanoma?
     Ann Surg Oncol. 2022 Jan 17. pii: 10.1245/s10434-021-11300.
     PubMed    
     
     
     
137. KARAKOUSIS G, Zager J
     Prognostic Biomarkers in Melanoma: The Legacy of a Surgeon Scientist Who Followed the Data.
     Ann Surg Oncol. 2022 Jan 2. pii: 10.1245/s10434-021-11273.
     PubMed    
     
     
     
138. DAVIS CH, Ho J, Greco SH, Koshenkov VP, et al
     ASO Visual Abstract: COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States.
     Ann Surg Oncol. 2022 Jan 1. pii: 10.1245/s10434-021-11179.
     PubMed    
     
     
     December 2021
139. SABEL MS
     Genomic Expression Profiling in Melanoma and the Road to Clinical Practice.
     Ann Surg Oncol. 2021 Dec 1. pii: 10.1245/s10434-021-11099.
     PubMed    
     
     
     November 2021
140. HIEKEN TJ, Price DL, Piltin MA, Turner HJ, et al
     ASO Visual Abstract: Surgeon Assessment of the Technical Impact of Neoadjuvant Systemic Therapy on Operable Stage III Melanoma.
     Ann Surg Oncol. 2021 Nov 30. pii: 10.1245/s10434-021-11146.
     PubMed    
     
     
     
141. MONCRIEFF M, Pywell S, Snelling A, Gray M, et al
     ASO Author Reflections: Effectiveness of SPECT/CT Imaging for Sentinel Node Biopsy Staging of Primary Cutaneous Melanoma and Patient Outcomes.
     Ann Surg Oncol. 2021 Nov 29. pii: 10.1245/s10434-021-11026.
     PubMed    
     
     
     
142. GUERRA F, Marra U, Giuliani G, Coratti A, et al
     Robotic Extended Ultrasound-Guided Distal Pancreatectomy for Pancreatic Metastases from Uveal Melanoma.
     Ann Surg Oncol. 2021 Nov 27. pii: 10.1245/s10434-021-11116.
     PubMed     Abstract available
     
     
     
143. HIEKEN TJ, Price DL, Piltin MA, Turner HJ, et al
     Surgeon Assessment of the Technical Impact of Neoadjuvant Systemic Therapy on Operable Stage III Melanoma.
     Ann Surg Oncol. 2021 Nov 25. pii: 10.1245/s10434-021-11112.
     PubMed     Abstract available
     
     
     
144. CARR MJ, Sun J, DePalo D, Rothermel LD, et al
     ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience.
     Ann Surg Oncol. 2021 Nov 24. pii: 10.1245/s10434-021-11036.
     PubMed    
     
     
     
145. MIURA J, Karakousis G
     Melanoma Surgery in the Emerging Era of Effective Neoadjuvant Therapy.
     Ann Surg Oncol. 2021 Nov 23. pii: 10.1245/s10434-021-11119.
     PubMed    
     
     
     
146. HIEKEN TJ, Piltin MA, Block MS
     ASO Author Reflections: Adding Value to Multidisciplinary Care by Incorporating Structured Surgeon Survey Assessment of the Effect of Neoadjuvant Therapies on Melanoma Operations.
     Ann Surg Oncol. 2021 Nov 20. pii: 10.1245/s10434-021-11117.
     PubMed    
     
     
     
147. DAVIS CH, Ho J, Greco SH, Koshenkov VP, et al
     COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States.
     Ann Surg Oncol. 2021 Nov 19. pii: 10.1245/s10434-021-11086.
     PubMed     Abstract available
     
     
     
148. MONCRIEFF M, Pywell S, Snelling A, Gray M, et al
     ASO Visual Abstract: Effectiveness of SPECT/CT Imaging for Sentinel Node Biopsy Staging of Primary Cutaneous Melanoma and Patient Outcomes.
     Ann Surg Oncol. 2021 Nov 11. pii: 10.1245/s10434-021-10957.
     PubMed    
     
     
     October 2021
149. MONCRIEFF M, Pywell S, Snelling A, Gray M, et al
     Effectiveness of SPECT/CT Imaging for Sentinel Node Biopsy Staging of Primary Cutaneous Melanoma and Patient Outcomes.
     Ann Surg Oncol. 2021 Oct 26. pii: 10.1245/s10434-021-10911.
     PubMed     Abstract available
     
     
     
150. CARR MJ, Sun J, DePalo D, Rothermel LD, et al
     Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience.
     Ann Surg Oncol. 2021 Oct 14. pii: 10.1245/s10434-021-10910.
     PubMed     Abstract available
     
     
     
151. CARR MJ, Zager JS
     ASO Author Reflections: T-VEC as Salvage for Progression of Locoregionally Metastatic Melanoma After Failure of Immunotherapy.
     Ann Surg Oncol. 2021 Oct 11. pii: 10.1245/s10434-021-10913.
     PubMed    
     
     
     September 2021
152. TORPHY RJ, Friedman C, Ho F, Leonard LD, et al
     ASO Visual Abstract: Adjuvant Therapy for Stage III Melanoma without Immediate Completion Lymph Node Dissection.
     Ann Surg Oncol. 2021 Sep 26. pii: 10.1245/s10434-021-10854.
     PubMed    
     
     
     
153. TORPHY RJ, McCarter MD, Gleisner AL
     ASO Author Reflections: Adjuvant Therapy for Stage III Melanoma With or Without Completion Lymph Node Dissection.
     Ann Surg Oncol. 2021 Sep 24. pii: 10.1245/s10434-021-10838.
     PubMed    
     
     
     
154. TORPHY RJ, Friedman C, Ho F, Leonard LD, et al
     Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection.
     Ann Surg Oncol. 2021 Sep 19. pii: 10.1245/s10434-021-10775.
     PubMed     Abstract available
     
     
     
155. EGGER ME
     Prognosis in Thin Melanoma Patients: Is Slightly Less Than Excellent Still Okay?
     Ann Surg Oncol. 2021 Sep 15. pii: 10.1245/s10434-021-10772.
     PubMed    
     
     
     
156. BROMAN KK, Bettampadi D, Perez-Morales J, Sun J, et al
     ASO Visual Abstract: Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection.
     Ann Surg Oncol. 2021 Sep 2. pii: 10.1245/s10434-021-10695.
     PubMed    
     
     
     August 2021
157. LI AT, Vakharia K, Lo SN, Varey AHR, et al
     ASO Visual Abstract: Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma.
     Ann Surg Oncol. 2021 Aug 10. pii: 10.1245/s10434-021-10529.
     PubMed    
     
     
     
158. CH'NG S, Scolyer RA, Thompson JF
     ASO Author Reflections: Surgical Resection May Improve the Outcome for Patients with Residual Metastatic Melanoma When Modern Systemic Therapies Have Not Achieved Complete Disease Control.
     Ann Surg Oncol. 2021 Aug 9. pii: 10.1245/s10434-021-10514.
     PubMed    
     
     
     
159. THOMPSON JF
     In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?
     Ann Surg Oncol. 2021 Aug 7. pii: 10.1245/s10434-021-10572.
     PubMed    
     
     
     
160. BROMAN KK, Bettampadi D, Perez-Morales J, Sun J, et al
     Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection.
     Ann Surg Oncol. 2021 Aug 6. pii: 10.1245/s10434-021-10570.
     PubMed     Abstract available
     
     
     
161. MOJTAHED SA, Boyer NR, Rao SA, Gajewski TF, et al
     ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients.
     Ann Surg Oncol. 2021 Aug 5. pii: 10.1245/s10434-021-10345.
     PubMed    
     
     
     
162. LI AT, Vakharia K, Lo SN, Varey AHR, et al
     Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma.
     Ann Surg Oncol. 2021 Aug 4. pii: 10.1245/s10434-021-10489.
     PubMed     Abstract available
     
     
     July 2021
163. ZAGER JS
     The Surgeons' Role When Systemic Therapies Fail in Metastatic Melanoma: The Salvage Metastasectomy.
     Ann Surg Oncol. 2021 Jul 21. pii: 10.1245/s10434-021-10491.
     PubMed    
     
     
     June 2021
164. ASARE EA, Swami U, Stewart JH 4th
     Landmark Series on Disparities in Surgical Oncology: Melanoma.
     Ann Surg Oncol. 2021 Jun 30. pii: 10.1245/s10434-021-10273.
     PubMed     Abstract available
     
     
     
165. ASARE EA, Stewart JH 4th
     ASO Author Reflections: Melanoma Killed Bob Marley and Others Too.
     Ann Surg Oncol. 2021 Jun 26. pii: 10.1245/s10434-021-10283.
     PubMed    
     
     
     
166. MOJTAHED SA, Boyer NR, Rao SA, Gajewski TF, et al
     Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients.
     Ann Surg Oncol. 2021 Jun 15. pii: 10.1245/s10434-021-10288.
     PubMed     Abstract available
     
     
     
167. SHARMA AS, Flynn JR, Panageas KS, Shahrokni A, et al
     ASO Visual Abstract: Assessment of Frailty Can Guide Decision Making for Utilization of Sentinel Lymph Node Biopsy in Patients with Thick Melanoma.
     Ann Surg Oncol. 2021 Jun 9. pii: 10.1245/s10434-021-10237.
     PubMed    
     
     
     
168. SHARMA AS, Flynn JR, Panageas KS, Shahrokni A, et al
     Assessment of Frailty Can Guide Decision Making for Utilization of Sentinel Lymph Node Biopsy in Patients with Thick Melanoma.
     Ann Surg Oncol. 2021 Jun 3. pii: 10.1245/s10434-021-10212.
     PubMed     Abstract available
     
     
     May 2021
169. EGGER ME
     The Role of Clinical Prediction Tools to Risk Stratify Patients with Melanoma After a Positive Sentinel Lymph Node Biopsy.
     Ann Surg Oncol. 2021 May 28. pii: 10.1245/s10434-018-07099.
     PubMed    
     
     
     
170. BROWN H, Pitney T, Muir J
     Base Transection with Shaves: An Avoidable Shortcoming : Reply to Impact of Shave Biopsy on Diagnosis and Management of Cutaneous Melanoma: A Systematic Review and Meta-analysis.
     Ann Surg Oncol. 2021 May 24. pii: 10.1245/s10434-021-10180.
     PubMed    
     
     
     
171. HERB JN, Ollila DW, Stitzenberg KB, Meyers MO, et al
     ASO Visual Abstract: Use and Costs of Sentinel Lymph Node Biopsy in Nonulcerated T1b Melanoma: Analysis of a Population-Based Registry.
     Ann Surg Oncol. 2021 May 14. pii: 10.1245/s10434-021-10061.
     PubMed    
     
     
     
172. DIENG M, Lord SJ, Nieweg OE, Saw RPM, et al
     Reply to: CT and PET/CT Surveillance in Stage IIIA-D Melanoma Results in More False-Positive Than True-Positive Findings and Should Not be Routinely Recommended, by Nicholas Taylor et al.
     Ann Surg Oncol. 2021 May 2. pii: 10.1245/s10434-021-09821.
     PubMed    
     
     
     April 2021
173. HERB JN, Ollila DW, Stitzenberg KB, Meyers MO, et al
     Use and Costs of Sentinel Lymph Node Biopsy in Non-Ulcerated T1b Melanoma: Analysis of a Population-Based Registry.
     Ann Surg Oncol. 2021 Apr 26. pii: 10.1245/s10434-021-09998.
     PubMed     Abstract available
     
     
     
174. LEE AY, Friedman EB, Sun J, Potdar A, et al
     Correction to: The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma.
     Ann Surg Oncol. 2021 Apr 23. pii: 10.1245/s10434-021-10047.
     PubMed    
     
     
     
175. EGGER ME
     Sentinel Lymph Node Biopsy for Thin Melanoma-Some Need It, Some Don't. So Now What?
     Ann Surg Oncol. 2021 Apr 22. pii: 10.1245/s10434-021-10038.
     PubMed    
     
     
     
176. MITRA D, Ologun G, Keung EZ, Goepfert RP, et al
     Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era.
     Ann Surg Oncol. 2021 Apr 15. pii: 10.1245/s10434-021-09804.
     PubMed     Abstract available
     
     
     
177. SHANNON AB, Wood C, Straker RJ 3rd, Miura JT, et al
     Age and Mitogenicity are Important Predictors of Sentinel Lymph Node Metastasis in T1a Melanoma.
     Ann Surg Oncol. 2021 Apr 8. pii: 10.1245/s10434-021-09929.
     PubMed    
     
     
     
178. AHMADI O, Mathy JA
     ASO Author Reflections: Diagnosis of Melanoma Using Shave Biopsy has Minimal Impact on Tumor Staging and Treatment and Does Not Influence Patient Outcomes.
     Ann Surg Oncol. 2021 Apr 1. pii: 10.1245/s10434-021-09935.
     PubMed    
     
     
     March 2021
179. AHMADI O, Das M, Hajarizadeh B, Mathy JA, et al
     Impact of Shave Biopsy on Diagnosis and Management of Cutaneous Melanoma: A Systematic Review and Meta-Analysis.
     Ann Surg Oncol. 2021 Mar 29. pii: 10.1245/s10434-021-09866.
     PubMed     Abstract available
     
     
     
180. HARRELL SHRECKENGOST C, Lowe MC
     ASO Author Reflections: Cutaneous Melanoma as Model System for the Obesity Paradox in Cancer.
     Ann Surg Oncol. 2021 Mar 21. pii: 10.1245/s10434-021-09818.
     PubMed     Abstract available
     
     
     
181. TAYLOR NA, Brodland DG
     CT and PET-CT Surveillance in Stages 3A to 3D Melanoma Results in More False-Positive than True-Positive Findings and Should Not be Routinely Recommended.
     Ann Surg Oncol. 2021 Mar 18. pii: 10.1245/s10434-021-09820.
     PubMed    
     
     
     
182. HARRELL SHRECKENGOST CS, Tariq M, Farley CR, Zhang C, et al
     The Impact of Obesity on Surgically Treated Locoregional Melanoma.
     Ann Surg Oncol. 2021 Mar 14. pii: 10.1245/s10434-021-09773.
     PubMed     Abstract available
     
     
     
183. FARROW NE, Rhodin KE, Beasley GM
     Nodal Recurrence as Primary Driver of Early Relapse in Patients with SLN-Positive Melanoma: What Does It Mean for Providers and Patients?
     Ann Surg Oncol. 2021 Mar 12. pii: 10.1245/s10434-021-09806.
     PubMed    
     
     
     February 2021
184. VREELAND TJ, Clifton GT, Hale DF, Chick RC, et al
     A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis.
     Ann Surg Oncol. 2021 Feb 27. pii: 10.1245/s10434-021-09709.
     PubMed     Abstract available
     
     
     
185. ADAMS AM, Vreeland TJ, Clifton GT, Peoples GE, et al
     ASO Author Reflections: The Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine for Advanced-Stage Melanoma: Reflection on Personalized Cancer Vaccination.
     Ann Surg Oncol. 2021 Feb 26. pii: 10.1245/s10434-021-09782.
     PubMed    
     
     
     January 2021
186. KANGAS-DICK AW, Greenbaum A, Gall V, Groisberg R, et al
     Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma.
     Ann Surg Oncol. 2021 Jan 23. pii: 10.1245/s10434-020-09563.
     PubMed     Abstract available
     
     
     
187. FARROW NE, Beasley GM
     ASO Author Reflections: Gene Expression-Profiling and Implications for Adjuvant Therapy in Melanoma.
     Ann Surg Oncol. 2021 Jan 22. pii: 10.1245/s10434-021-09595.
     PubMed    
     
     
     
188. KANGAS-DICK A, Berger AC, Koshenkov V
     ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?
     Ann Surg Oncol. 2021 Jan 21. pii: 10.1245/s10434-021-09599.
     PubMed    
     
     
     
189. LI W, Xu X, Zhang Y
     Novel Prognostic Models Predicting the Cancer-Specific Survival in Patients with Cutaneous Melanoma Based on Metastatic Lymph Node Status.
     Ann Surg Oncol. 2021 Jan 11. pii: 10.1245/s10434-020-09556.
     PubMed     Abstract available
     
     
     
190. TURNER RM, Dieng M, Khanna N, Nguyen M, et al
     Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma.
     Ann Surg Oncol. 2021 Jan 3. pii: 10.1245/s10434-020-09270.
     PubMed     Abstract available
     
     
     
191. DIENG M, Morton RL
     ASO Author Reflections: Longitudinal Diagnostic Accuracy of Surveillance Imaging in Resected Stage III Melanoma Patients.
     Ann Surg Oncol. 2021 Jan 2. pii: 10.1245/s10434-020-09407.
     PubMed    
     
     
     November 2020
192. STRAKER RJ 3RD, Song Y, Sun J, Shannon AB, et al
     Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era.
     Ann Surg Oncol. 2020 Nov 23. pii: 10.1245/s10434-020-09384.
     PubMed     Abstract available
     
     
     
193. FARROW NE, Holl EK, Jung J, Gao J, et al
     Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma.
     Ann Surg Oncol. 2020 Nov 17. pii: 10.1245/s10434-020-09277.
     PubMed     Abstract available
     
     
     
194. LI W, Xiao Y, Xu X, Zhang Y, et al
     A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Mortality of Patients with Initially Diagnosed Metastatic Cutaneous Melanoma.
     Ann Surg Oncol. 2020 Nov 15. pii: 10.1245/s10434-020-09341.
     PubMed     Abstract available
     
     
     October 2020
195. NIJHUIS AAG, Thompson JF, Nieweg OE
     ASO Author Reflections: Ultrasound Assessment of the Lymphatic Drainage Area in Melanoma Patients With In-Transit Metastases.
     Ann Surg Oncol. 2020 Oct 29. pii: 10.1245/s10434-020-09246.
     PubMed    
     
     
     
196. NIJHUIS A, Chung D, London K, Uren R, et al
     Ultrasound Examination of the Lymphatic Drainage Area and Regional Lymph Nodes in Melanoma Patients with In-Transit Metastases.
     Ann Surg Oncol. 2020 Oct 27. pii: 10.1245/s10434-020-09240.
     PubMed     Abstract available
     
     
     
197. LO M, Peach H, Moncrieff M
     ASO Author Reflections: Extracapsular Spread in Melanoma Lymphadenopathy: Prognostic Implications, Classification, and Management.
     Ann Surg Oncol. 2020 Oct 20. pii: 10.1245/s10434-020-09197.
     PubMed    
     
     
     
198. BOGACH J, Wright FC, Austin J, Cheng SY, et al
     Medical Immunosuppression and Outcomes in Cutaneous Melanoma: A Population-Based Cohort Study.
     Ann Surg Oncol. 2020 Oct 16. pii: 10.1245/s10434-020-09224.
     PubMed     Abstract available
     
     
     September 2020
199. STANDAGE H, Han D
     ASO Author Reflections: What is the Cost-Effective Treatment of Melanoma Patients with a Positive Sentinel Node?
     Ann Surg Oncol. 2020 Sep 24. pii: 10.1245/s10434-020-09168.
     PubMed    
     
     
     June 2020
200. VOTANOPOULOS KI, Forsythe S, Sivakumar H, Mazzocchi A, et al
     Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study.
     Ann Surg Oncol. 2020;27:1956-1967.
     PubMed     Abstract available
     
     
     May 2020
201. HELMINK BA, Roland CL, Kiernan CM, Wargo JA, et al
     Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon.
     Ann Surg Oncol. 2020;27:1533-1545.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.